Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway

APMIS

Volumn 121, Issue 4, 2013, Pages 353-358

  Larsen, Astri L ^a   Ragnhildstveit, Eivind ^a   Moayeri, Berouz ^b   Eliassen, Lisbeth ^a   Melby, Kjetil K ^b,c  

^a Ostfold Hospital Trust   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Amoxicillin; Antibiotic susceptibility; Clarithromycin; Helicobacter pylori; Metronidazole; Rifabutin and levofloxacin; Tetracycline

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; RIFABUTIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; HELICOBACTER PYLORI; HUMAN; INCUBATION TIME; NONHUMAN; NORWAY; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; NORWAY;

EID: 84875654859     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12009     Document Type: Article

References (25)

1. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322.
2. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.
3. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol 1999;34:353-60.
4. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007;56:918-25.
5. McNulty CA, Dent JC, Ford GA, Wilkinson SP. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988;22:729-38.
6. van Zanten SJ, Goldie J, Hollingsworth J, Siletti C, Richardson H, Hunt RH. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol 1992;45:225-7.
7. Grayson ML, Eliopoulos GM, Ferrraro MJ, Moellering RC Jr. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989;8:888-9.
8. Debets-Ossenkopp YJ, Namavar F, MacLaren DM. Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. Eur J Clin Microbiol Infect Dis 1995;14:353-5.
9. Megraud F, Trimoulet P, Lamouliatte H, Boyanova L. Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells. Antimicrob Agents Chemother 1991;35:869-72.
10. Bryskier A, Lowther J, Couturier C. H. pylori and antibacterial agents. In: Bryskier A, editor. Antimicrobial Agents: Antibacterials and Antifungals. Washington, DC: ASM Press, 2005: 1011-44.
11. Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 1992;29:115-20.
12. Rubinstein G, Dunkin K, Howard AJ. The susceptibility of Helicobacter pylori to 12 antimicrobial agents, omeprazole and bismuth salts. J Antimicrob Chemother 1994;34:409-13.
13. van Zwet AA, Thijs JC, de Graaf B. Explanations for high rates of eradication with triple therapy using metronidazole in patients harbouring metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother 1995;39:250-52.
14. Glupczynski Y, Broutet N, Cantagrel A, Andersen LP, Alarcon T, López-Brea M, et al. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002;21:549-52.
15. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection-the maastricht III consensus report. Gut 2007;56:772-81. doi:10.1136/gut.2006.101634.
16. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.
17. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut doi: 10.1136/gutjnl-2012-302254. [Epub ahead of print]
18. Tveten Y (ed). AFAs brytningspunkter for bakteriers antibiotikafølsomhet - versjon 1.13.1. Norwegian Working Group on Antibiotics (AFA). Report dated 11.11.2009 Table 17, Annex 15. ISBN 978-82-92345-14-6.
19. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters Version 2.0, valid from 2012-01-01.. http://www.eucast.org/clinical_breakpoints/ (accessed on 16 July 2012).
20. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European Multicentre Survey of in vitro Antimicrobial Resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3.
21. European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of microorganisms. http://www.eucast.org/mic_distributions/ (accessed on 16 July 2012).
22. Glocker E, Bogdan D, Kist M. Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. J Antimicrob Chemother 2007;59:874-9.
23. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-1384.
24. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006;6:699-709.
25. Albert TJ, Dailidiene D, Dailide G, Norton JE, Kalia A, Richmond TA, et al. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nat Methods 2005 Dec;2:951-3.